Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives

被引：8
作者：
Chen, Jian-Jian [1 ]
Jin, Zhi-Cheng [1 ]
Zhong, Bin-Yan [2 ]
Fan, Wenzhe [3 ]
Zhang, Wei-Hua [1 ]
Luo, Biao [1 ]
Wang, Yu-Qing [1 ]
Teng, Gao-Jun [1 ]
Zhu, Hai-Dong [1 ]
机构：
[1] Southeast Univ, Ctr Intervent Radiol & Vasc Surg, Zhongda Hosp, Dept Radiol,Med Sch, Nanjing 210009, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Intervent Radiol, Suzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou, Peoples R China
来源：
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL | 2024年 / 12卷 / 02期
基金：
中国国家自然科学基金;
关键词：
combined modality therapy; hepatocellular carcinoma; immune checkpoint inhibitors; locoregional therapy; molecular targeted therapy; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; RANDOMIZED CONTROLLED-TRIAL; INTERNAL RADIATION-THERAPY; VEIN TUMOR THROMBOSIS; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; CONVENTIONAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; IRRADIATION STENT; ELUTING BEADS;
D O I：
10.1002/ueg2.12554
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.
引用
收藏
页码：226 / 239
页数：14
相关论文
共 100 条
  • [61] Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma
    Millonig, Gunda
    Graziadei, Ivo W.
    Freund, Martin C.
    Jaschke, Werner
    Stadlmann, Sylvia
    Ladurner, Ruth
    Margreiter, Raimund
    Vogel, Wolfgang
    [J]. LIVER TRANSPLANTATION, 2007, 13 (02) : 272 - 279
  • [62] National Comprehensive Cancer Network (NCCN), 2023, NCCN GUIDELINES VERS
  • [63] Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
    Nault, Jean-Charles
    Sutter, Olivier
    Nahon, Pierre
    Ganne-Carrie, Nathalie
    Seror, Olivier
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 783 - 797
  • [64] Current Status of Hepatic Arterial Infusion Chemotherapy
    Obi, Shuntaro
    Sato, Shinpei
    Kawai, Toshihiro
    [J]. LIVER CANCER, 2015, 4 (03) : 188 - 199
  • [65] Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial
    Peng, Zhen-Wei
    Zhang, Yao-Jun
    Chen, Min-Shan
    Xu, Li
    Liang, Hui-Hong
    Lin, Xiao-Jun
    Guo, Rong-Ping
    Zhang, Ya-Qi
    Lau, Wan Yee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 426 - 432
  • [66] Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and RF Ablation versus RF Ablation Alone: A Prospective Randomized Trial
    Peng, Zhen-Wei
    Zhang, Yao-Jun
    Liang, Hui-Hong
    Lin, Xiao-Jun
    Guo, Rong-Ping
    Chen, Min-Shan
    [J]. RADIOLOGY, 2012, 262 (02) : 689 - 700
  • [67] Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial
    Peng, Zhenwei
    Fan, Wenzhe
    Zhu, Bowen
    Li, Jiaping
    Kuang, Ming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [68] Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
    Pinato, David J.
    Murray, Sam M.
    Forner, Alejandro
    Kaneko, Takahiro
    Fessas, Petros
    Toniutto, Pierluigi
    Minguez, Beatriz
    Cacciato, Valentina
    Avellini, Claudio
    Diaz, Alba
    Boyton, Rosemary J.
    Altmann, Daniel M.
    Goldin, Robert D.
    Akarca, Ayse U.
    Marafioti, Teresa
    Mauri, Francesco A.
    Casagrande, Edoardo
    Grillo, Federica
    Giannini, Edoardo
    Bhoori, Sherrie
    Mazzaferro, Vincenzo
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [69] Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation
    Pompili, Maurizio
    Francica, Giampiero
    Ponziani, Francesca Romana
    Iezzi, Roberto
    Avolio, Alfonso Wolfango
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (43) : 7515 - 7530
  • [70] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial
    Qin, Shukui
    Chen, Minshan
    Cheng, Ann-Lii
    Kaseb, Ahmed
    Kudo, Masatoshi
    Lee, Han Chu
    Yopp, Adam C.
    Zhou, Jian
    Wang, Lu
    Wen, Xiaoyu
    Heo, Jeong
    Tak, Won Young
    Nakamura, Shinichiro
    Numata, Kazushi
    Uguen, Thomas
    Hsiehchen, David
    Cha, Edward
    Hack, Stephen P.
    Lian, Qinshu
    Ma, Ning
    Spahn, Jessica H.
    Wang, Yulei
    Wu, Chun
    Chow, Pierce K. H.
    [J]. LANCET, 2023, 402 (10415) : 1835 - 1847
12345678910